NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Price Performance

NBY opened at $0.67 on Friday. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $12.22. The business has a 50-day moving average of $0.62 and a two-hundred day moving average of $1.68. The stock has a market capitalization of $3.28 million, a price-to-earnings ratio of -0.01 and a beta of 0.73.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. The company had revenue of $2.40 million for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 744.33% and a negative net margin of 91.86%. Equities research analysts anticipate that NovaBay Pharmaceuticals will post -1.41 earnings per share for the current year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.